Literature DB >> 22263044

Targeting the tumor vascular supply with vascular disrupting agents.

Ross A Soo1.   

Abstract

Entities:  

Year:  2010        PMID： 22263044      PMCID： PMC3256470          DOI： 10.3978/j.issn.2072-1439.2010.11.1

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

Authors:  Mark J McKeage; Michael B Jameson
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

2.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Authors:  Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 3.  Differentiation and definition of vascular-targeted therapies.

Authors:  Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

4.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

5.  Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Authors:  Mark J McKeage; Martin Reck; Michael B Jameson; Mark A Rosenthal; David Gibbs; Paul N Mainwaring; Lutz Freitag; Richard Sullivan; Joachim Von Pawel
Journal:  Lung Cancer       Date:  2009-05-05       Impact factor: 5.705

6.  Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  M Philpott; B C Baguley; L M Ching
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 8.  Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.

Authors:  Cesare Gridelli; Antonio Rossi; Paolo Maione; Emanuela Rossi; Vincenzo Castaldo; Paola Claudia Sacco; Giuseppe Colantuoni
Journal:  Oncologist       Date:  2009-05-27

9.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Authors:  M J McKeage; J Von Pawel; M Reck; M B Jameson; M A Rosenthal; R Sullivan; D Gibbs; P N Mainwaring; M Serke; J-J Lafitte; C Chouaid; L Freitag; E Quoix
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.